XOMA Corp (NASDAQ:XOMA) Expected to Post Earnings of -$0.28 Per Share
Brokerages expect that XOMA Corp (NASDAQ:XOMA) will announce ($0.28) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for XOMA’s earnings, with estimates ranging from ($0.41) to ($0.21). XOMA reported earnings of ($0.35) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 20%. The firm is expected to announce its next earnings results on Thursday, March 5th.
According to Zacks, analysts expect that XOMA will report full-year earnings of ($0.22) per share for the current financial year, with EPS estimates ranging from ($0.44) to $0.03. For the next fiscal year, analysts forecast that the business will report earnings of ($1.05) per share, with EPS estimates ranging from ($1.28) to ($0.85). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow XOMA.
XOMA (NASDAQ:XOMA) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.68. XOMA had a negative net margin of 10.19% and a negative return on equity of 8.93%. The company had revenue of $8.86 million for the quarter.
In related news, CFO Thomas M. Burns sold 3,829 shares of the company’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $21.96, for a total transaction of $84,084.84. Following the transaction, the chief financial officer now owns 10,384 shares of the company’s stock, valued at $228,032.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James R. Neal sold 4,348 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $22.00, for a total value of $95,656.00. Following the completion of the transaction, the chief executive officer now owns 22,017 shares of the company’s stock, valued at approximately $484,374. The disclosure for this sale can be found here. In the last 90 days, insiders sold 17,459 shares of company stock valued at $374,142. 9.89% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of XOMA. RBF Capital LLC acquired a new stake in XOMA during the 2nd quarter valued at $1,479,000. Stonepine Capital Management LLC lifted its holdings in XOMA by 18.9% in the 2nd quarter. Stonepine Capital Management LLC now owns 270,449 shares of the biotechnology company’s stock worth $4,019,000 after buying an additional 43,019 shares in the last quarter. Paloma Partners Management Co acquired a new stake in shares of XOMA during the second quarter valued at about $510,000. Marshall Wace LLP acquired a new stake in XOMA during the 2nd quarter valued at approximately $434,000. Finally, Morgan Stanley grew its stake in XOMA by 2,151.6% during the 2nd quarter. Morgan Stanley now owns 23,889 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 22,828 shares in the last quarter. Institutional investors own 37.20% of the company’s stock.
Shares of XOMA traded down $0.14 during mid-day trading on Friday, hitting $23.82. 3,186 shares of the company’s stock were exchanged, compared to its average volume of 60,915. The company has a current ratio of 4.37, a quick ratio of 4.37 and a debt-to-equity ratio of 1.31. XOMA has a fifty-two week low of $11.02 and a fifty-two week high of $26.90. The business’s 50 day moving average is $21.99 and its two-hundred day moving average is $18.76. The firm has a market capitalization of $209.35 million, a P/E ratio of -15.14 and a beta of 1.27.
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.
Further Reading: What is a Candlestick Chart?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.